Dahlman, Kimberly B.

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 1,454

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 982

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 396

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides

McGirt, L. Y., Jia, P., Baerenwald, D. A., Duszynski, R. J., Dahlman, K. B., Zic, J. A., Zwerner, J. P., Hucks, D., Dave, U., Zhao, Z., et al. (2015) · Blood

Cutaneous lymphoproliferative disorders researchLymphoma Diagnosis and Treatment

Cited by 232

A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Xia, J., Jia, P., Hutchinson, K. E., Dahlman, K. B., Johnson, D., Sosman, J., Pao, W., & Zhao, Z. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 94

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma

Giricz, O., Mo, Y., Dahlman, K. B., Cotto-Rios, X. M., Vardabasso, C., Nguyen, H., Matusow, B., Bartenstein, M., Polishchuk, V., Johnson, D. B., et al. (2018) · JCI Insight

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 40